|
34 Confidential
Proxy Solicitation In connection with the proposed merger, Sonus filed with
the SEC a Proxy Statement and related materials on July 3, 2008 containing
information about Sonus, OncoGenex and the proposed merger. Sonus mailed the
Proxy Statement to its stockholders on or about July 9, 2008. INVESTORS AND
SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND THE OTHER RELEVANT
MATERIALS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT
INFORMATION ABOUT SONUS, ONCOGENEX AND THE PROPOSED MERGER. Sonus and
OncoGenex, and certain of their directors, executive officers and other
members of management and employees may be deemed to be participants in the
solicitation of proxies in connection with the proposed transaction.
Information about the directors and executive officers of Sonus, including
their respective security holdings, is set forth in Sonus Amendment No. 1 to
Form 10-K for the fiscal year ended December 31, 2007, filed with the SEC on
April 29, 2008, and the Proxy Statement filed with the SEC on July 3, 2008.
As of June 30, 2008, OncoGenex directors and executive officers beneficially
owned approximately 1,755,000 shares, or 14.5%, of OncoGenex capital stock.
Investors may obtain additional information regarding the interests of
OncoGenex, Sonus and their respective executive officers and directors in the
merger by reading the Proxy Statement for such proposed transaction. The
Proxy Statement and other relevant materials, and any other documents filed
by Sonus with the SEC, may be obtained free of charge at the SEC's web site
at www.sec.gov. In addition, investors and security holders may obtain free
copies of the documents filed with the SEC by Sonus by directing a request
to: Sonus Pharmaceuticals, Inc., 1522 217th Place SE, Suite 100, Bothell, WA
98021, Phone (425) 686-1500, Fax (425) 686-1600, Attention: Investor
Relations.
|